艾萬霖生技股份有限公司成立於2020年12月,董事長林奏延醫師是知名的小兒科權威醫師,擔任過多項要職,包括行政院衛生福利部部長、國家衛生研究院董事長、台灣感染症醫學會理事長、及台灣兒科醫學會理事長。艾萬霖生技股份有限公司是以外泌體為主要研發項目的公司,願景是成為全球抗老化與回春領導重鎮,使命是運用優質外泌體生技產品治療退化性疾病與維持健康的老化。艾萬霖生技公司的外泌體新藥也是台灣衛生福利部 (TFDA)第一個外泌體新藥申請案件,因此醫藥品查驗中心(CDE)將之列為新藥指標案件,未來政府將協助艾萬霖進行外泌體新藥的開發,並共同建立相關的新藥審查法規。
2020 | ExoOne Bio Co., Ltd. established in Linkou, New Taipei City |
2021 | ExoOne Bio’s exosome new drug development selected by CDE as an Index Project |
2021 | Established an independent in-house exosome research & development Lab. |
2021 | Sign academia collaboration agreement on research & development with several institutes |
2022 | ExoOne Bio signs CDMO agreement with Taiwan Bio Therapeutics Co., Ltd. |
2022 | Sign collaboration agreement for new drug pre-clinical development with several institutes |
2022 | Cosmetic functional assays completed |
2022 | Cosmetic human clinical studies ongoing |
2022 | Cosmetic data submitted for publication |
2023 | Exosome biodistribution data completed |
2023 | Approved by Ministry of Economic Affairs as a qualified biotech company |
2023 | Fund raising to NT$120Mil. |
2023 | Exosome functional studies in osteoarthritis、degenerative eye diseases、& anti-aging completed |
2023 | ExoHair Essence study ongoing |